Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Ionis Pharmaceuticals Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 47.27 · gapped above the open, then crossed back over prior close. High/low 51.85 at 4:00 am ET, 46.88 at 3:30 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Biogen manufactures the finished drug product for SPINRAZA and QALSODY and AstraZeneca is responsible for WAINUA's commercial drug supply.”
FILING10-K0000874015-26-000115cik 0000874015
“Biogen manufactures the finished drug product for SPINRAZA and QALSODY and AstraZeneca is responsible for WAINUA's commercial drug supply.”
FILING10-K0000874015-26-000115cik 0000874015
“We have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts.”
FILING10-K0000874015-26-000115cik 0000874015
“We have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts.”
FILING10-K0000874015-26-000115cik 0000874015
“Our WAINUA joint development revenue in 2024 included a $30 million milestone payment from AstraZeneca that we earned when the Medicines and Healthcare products Regulatory Agency, or MHRA, approved WAINUA for ATTRv-PN in the UK as WAINZUA.”
FILING10-K0000874015-26-000115cik 0000874015
“For TEGSEDI's commercial drug supply, we are using CMOs to produce API and finished goods for Sobi and PTC.”
FILING10-K0000874015-26-000115cik 0000874015
“Under our collaboration agreement with Ionis, we reimbursed Ionis for identifying a development candidate and conducting an investigational new drug application, or IND, enabling toxicology study, as well as out of pocket costs incurred by Ionis related to research activities.”
FILING10-K0001689548-26-000029cik 0001689548disclosed by PRAX
“The remainder of our revenue came from programs under our R&D collaborations, including a $280 million upfront payment for the global license of sapablursen to Ono in the second quarter of 2025, reflecting the value that our pipeline and technology continues to generate.”
FILING10-K0000874015-26-000115cik 0000874015
“For DAWNZERA's commercial drug supply, we are using CMOs to produce API and finished goods for ourselves and Otsuka.”
FILING10-K0000874015-26-000115cik 0000874015
“Under our agreements, we are responsible for supplying finished goods inventory to Sobi and Sobi is responsible for selling each medicine to the end customer.”
FILING10-K0000874015-26-000115cik 0000874015
“Under the terms of our agreement with Alnylam, each party licensed to the other party its early patent estate relating to oligonucleotide chemistry for specified uses (generally, single-stranded ASOs for us and siRNA for Alnylam).”
FILING10-K0000874015-26-000115cik 0000874015
“For example, in November 2022, we entered into a Collaboration and License Agreement with Ionis Pharmaceuticals, Inc. ("Ionis") to research, develop and commercialize investigational medicines using our genome editing technologies.”
FILING10-K0001193125-26-093976cik 0001785279disclosed by MGX
“For example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.”
FILING10-K0000874015-26-000115cik 0000874015
“For example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.”
FILING10-K0000874015-26-000115cik 0000874015
“As a result, we paid Metagenomi to license its technologies and will pay Metagenomi certain fees for the selection of genetic targets.”
FILING10-K0000874015-26-000115cik 0000874015
“For example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.”
FILING10-K0000874015-26-000115cik 0000874015
“For example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.”
FILING10-K0000874015-26-000115cik 0000874015
“For example, we use clinical research organizations, such as Icon Clinical Research Limited, Medpace, Inc., Parexel International Corporation, Syneos Health, Inc. and Thermo Fisher Scientific Inc. for the clinical studies for our medicines, including WAINUA for the treatment of ATTR-CM, DAWNZERA, obudanersen, olezarsen, ulefnersen and zilganersen.”
FILING10-K0000874015-26-000115cik 0000874015
“In December 2023, we entered into a license agreement with Vect-Horus to provide us with a worldwide, exclusive license for a specified number of targets using Vect-Horus' technology for systemic delivery of RNA-targeted therapeutics that may cross the blood-brain barrier and address targets in the central nervous system.”
FILING10-K0000874015-26-000115cik 0000874015
“In 2023, we entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our agreements with Biogen and Novartis, respectively.”
FILING10-K0000874015-26-000115cik 0000874015
“For example, in the past we have manufactured clinical trial material for AstraZeneca, Biogen, GSK, Roche, and Novartis and commercial drug supply for Biogen.”
FILING10-K0000874015-26-000115cik 0000874015
“In 2023, we entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our agreements with Biogen and Novartis, respectively.”
FILING10-K0000874015-26-000115cik 0000874015
“For example, in the past we have manufactured clinical trial material for AstraZeneca, Biogen, GSK, Roche, and Novartis and commercial drug supply for Biogen.”
FILING10-K0000874015-26-000115cik 0000874015
“In 2021, we exercised our option to license Bicycle's technology.”
FILING10-K0000874015-26-000115cik 0000874015
Watchlist prices, news filtered to it, and its next report on your desk.
Ionis Pharmaceuticals Inc has 14 disclosed suppliers and 10 disclosed customers. Each one is named in an SEC filing, either Ionis Pharmaceuticals Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
IONS (Ionis Pharmaceuticals Inc) has 14 disclosed suppliers and 10 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PRAX −4.86%, in healthcare.